novartis_window

Glenmark signs deal with Novartis over distribution in Brazil

pharmafile | June 24, 2019 | News story | Sales and Marketing Brazil, Glenmark, Latin America, Novartis, distribution, pharma 

Indian firm Glenmark Pharmaceuticals has entered into an agreement with Novartis over the distribution of its respiratory products in Brazil.

Novartis will distribute three of Glenmark’s COPD drugs in Brazil from 1 July 2019.

The Swiss firm will be responsible for promoting, commercialising and distributing Glenmark’s Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (combination of Indacaterol and Glycopyrronium) – all of which treat the symptoms of COPD.

Advertisement

“This partnership is in line with our vision to expand our respiratory product offerings for patients and prescribers in Brazil and further consolidate our position in this segment,” said Glenn Saldanha, Chairman and Managing Director of Glenmark.

Glenmark receives around 5% of its revenue from Latin America. However Indian generic drugmakers – who are now facing pricing pressures in the US – are increasingly focused on increasing sales in big markets such as Brazil.

Louis Goss

Related Content

Novartis receives SMC approval for early breast cancer treatment

Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

drug-trials

LGC Group opens $100M Organic Chemistry Synthesis Centre of Excellence

LGC Group, a life sciences company, has opened its new Organic Chemistry Synthesis Centre of …

drug-trials

Novartis candidate for Sjögren’s disease presents positive results

Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …

The Gateway to Local Adoption Series

Latest content